The study showed that approximately 33 percent of MDD patients and 27 percent of BD patients were not adhering to their prescribed antipsychotic; for schizophrenia, the nonadherence rate was 19 percent. The findings were obtained from an analysis of over 3,600 unique urine samples.
"Clinicians should appreciate that nonadherence is a significant problem across the spectrum of serious mental illness.”
Ameritox is currently developing more comprehensive reference bases for antipsychotic metabolites, so clinicians can find out not only whether the drug is being taken, but also whether it is being taken properly.